罗氟司特-话题@MedSci - 梅斯（MedSci）

[GetTopicListResponse(id=1934131, encodeId=3bec1934131da, content=<a href='/topic/show?id=6e32e9618ba' target=_blank style='color:#2F92EE;'>#罗氟司特#</a>, objectTitle=NEJM：罗氟司特乳膏局部治疗可显著改善银屑病患者皮肤症状, objectType=article, longId=197644, objectId=031019e644e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=031019e644e6, replyNumber=0, likeNumber=90, createdTime=2020-08-10, rootId=0, userName=zhty5337, userId=ec53439, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=031019e644e6, moduleTitle=NEJM：罗氟司特乳膏局部治疗可显著改善银屑病患者皮肤症状, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=031019e644e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1934130, encodeId=b3d819341305e, content=<a href='/topic/show?id=6e32e9618ba' target=_blank style='color:#2F92EE;'>#罗氟司特#</a>, objectTitle=NEJM：罗氟司特局部乳膏治疗慢性斑块状牛皮癣的2b期阳性结果, objectType=article, longId=197622, objectId=ae3b19e62262, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae3b19e62262, replyNumber=0, likeNumber=84, createdTime=2021-06-27, rootId=0, userName=zhty5337, userId=ec53439, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae3b19e62262, moduleTitle=NEJM：罗氟司特局部乳膏治疗慢性斑块状牛皮癣的2b期阳性结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ae3b19e62262)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1934129, encodeId=a19519341294d, content=<a href='/topic/show?id=6e32e9618ba' target=_blank style='color:#2F92EE;'>#罗氟司特#</a>, objectTitle=Tuberc Respir Dis：250微克和500微克罗氟司特治疗患者的不良反应和中止率的发生率, objectType=article, longId=146357, objectId=88ef14635e4a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88ef14635e4a, replyNumber=0, likeNumber=70, createdTime=2018-12-31, rootId=0, userName=zhty5337, userId=ec53439, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88ef14635e4a, moduleTitle=Tuberc Respir Dis：250微克和500微克罗氟司特治疗患者的不良反应和中止率的发生率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=88ef14635e4a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1934128, encodeId=5ba319341288b, content=<a href='/topic/show?id=6e32e9618ba' target=_blank style='color:#2F92EE;'>#罗氟司特#</a>, objectTitle=罗氟司特获FDA批准将250 mcg作为初始剂量治疗慢性阻塞性肺病, objectType=article, longId=128116, objectId=398e12811613, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=398e12811613, replyNumber=0, likeNumber=93, createdTime=2018-09-09, rootId=0, userName=zhty5337, userId=ec53439, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=398e12811613, moduleTitle=罗氟司特获FDA批准将250 mcg作为初始剂量治疗慢性阻塞性肺病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=398e12811613)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1934127, encodeId=6c46193412e2d, content=<a href='/topic/show?id=6e32e9618ba' target=_blank style='color:#2F92EE;'>#罗氟司特#</a>, objectTitle=Pulm Pharmacol Ther：罗氟司特可减小哮喘患者过敏原诱导的气道炎症反应, objectType=article, longId=55727, objectId=7d6055e2799, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d6055e2799, replyNumber=0, likeNumber=72, createdTime=2015-12-17, rootId=0, userName=zhty5337, userId=ec53439, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d6055e2799, moduleTitle=Pulm Pharmacol Ther：罗氟司特可减小哮喘患者过敏原诱导的气道炎症反应, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7d6055e2799)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1934125, encodeId=cf82193412543, content=<a href='/topic/show?id=6e32e9618ba' target=_blank style='color:#2F92EE;'>#罗氟司特#</a>, objectTitle=Pulm Pharmacol Ther：闫俊红等发现罗氟司特能显著降低COPD患者平均恶化率, objectType=article, longId=20930, objectId=1fab2093032, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fab2093032, replyNumber=0, likeNumber=80, createdTime=2014-02-11, rootId=0, userName=zhty5337, userId=ec53439, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fab2093032, moduleTitle=Pulm Pharmacol Ther：闫俊红等发现罗氟司特能显著降低COPD患者平均恶化率, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1fab2093032)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1934126, encodeId=f9eb193412630, content=<a href='/topic/show?id=6e32e9618ba' target=_blank style='color:#2F92EE;'>#罗氟司特#</a>, objectTitle=Chest：钟南山等研究发现罗氟司特为重度至极重度亚裔COPD患者理想的治疗药物, objectType=article, longId=25833, objectId=97a62583310, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97a62583310, replyNumber=0, likeNumber=98, createdTime=2014-09-04, rootId=0, userName=zhty5337, userId=ec53439, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97a62583310, moduleTitle=Chest：钟南山等研究发现罗氟司特为重度至极重度亚裔COPD患者理想的治疗药物, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=97a62583310)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

罗氟司特

2020-05-29

zhty5337 (审核中...)

前往app查看评论内容

#罗氟司特#

NEJM：罗氟司特乳膏局部治疗可显著改善银屑病患者皮肤症状

2020-08-10

zhty5337 (审核中...)

前往app查看评论内容

#罗氟司特#

NEJM：罗氟司特局部乳膏治疗慢性斑块状牛皮癣的2b期阳性结果

2021-06-27

zhty5337 (审核中...)

前往app查看评论内容

#罗氟司特#

Tuberc Respir Dis：250微克和500微克罗氟司特治疗患者的不良反应和中止率的发生率

2018-12-31

zhty5337 (审核中...)

前往app查看评论内容

#罗氟司特#

罗氟司特获FDA批准将250 mcg作为初始剂量治疗慢性阻塞性肺病

2018-09-09

zhty5337 (审核中...)

前往app查看评论内容

#罗氟司特#

Pulm Pharmacol Ther：罗氟司特可减小哮喘患者过敏原诱导的气道炎症反应

2015-12-17

zhty5337 (审核中...)

前往app查看评论内容

#罗氟司特#

Pulm Pharmacol Ther：闫俊红等发现罗氟司特能显著降低COPD患者平均恶化率

2014-02-11

zhty5337 (审核中...)

前往app查看评论内容

#罗氟司特#

Chest：钟南山等研究发现罗氟司特为重度至极重度亚裔COPD患者理想的治疗药物

2014-09-04

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

#罗氟司特#

科室

工具

服务